Ultragenyx Pharmaceutical Inc. buy Royal Bank of Canada
Start price
22.04.24
/
50%
€41.20
Target price
22.04.25
€72.35
Performance (%)
-2.43%
Price
03.05.24
€39.80
Summary
This prediction is currently active. With a performance of -2.43%, the BUY prediction for Ultragenyx Pharmaceutical Inc. by Royal_Bank_of_Canada is down slightly. This prediction currently runs until 22.04.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w |
---|---|
Ultragenyx Pharmaceutical Inc. | -3.865% |
iShares Core DAX® | -0.922% |
iShares Nasdaq 100 | 0.371% |
iShares Nikkei 225® | 2.224% |
iShares S&P 500 | -0.026% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat